In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

Biogen is in advanced negotiations to consolidate its Kendall Square operations in MIT’s upcoming Volpe redevelopment, ...

Investing.com -- Stifel downgraded Biogen Inc (NASDAQ:BIIB) stock to “hold” from “buy” as it noted the company was grappling with a challenging year due to a slow rollout of its Alzheimer ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

At the forefront of Biogen's growth strategy is Leqembi, developed in partnership with Eisai for the treatment of early Alzheimer's disease. The drug's launch has been closely watched, with ...

Researchers used AI to analyze brain images from 70-year-olds, estimating their biological brain age and uncovering ...

Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.